Cargando…

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials

BACKGROUND: The objective of this analysis was to evaluate the efficacy and safety of oritavancin compared with vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSIs) who received treatment in the outpatient setting in the Phase 3 SOLO clinical trials. METHODS: SOL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lodise, Thomas P., Redell, Mark, Armstrong, Shannon O., Sulham, Katherine A., Corey, G. Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414048/ https://www.ncbi.nlm.nih.gov/pubmed/28480266 http://dx.doi.org/10.1093/ofid/ofw274

Ejemplares similares

Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas P, et al.
Publicado: (2019)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas, et al.
Publicado: (2018)

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis
por: Jensen, Ivar S., et al.
Publicado: (2016)

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program
por: Redell, Mark, et al.
Publicado: (2018)

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis
por: Jensen, Ivar S., et al.
Publicado: (2015)

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies
por: Huang, David B, et al.
Publicado: (2019)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

288. Expediting Discharge in Acute Bacterial Skin and Skin Structure Infections: A Clinical and Economic Comparison Between Vancomycin and Oritavancin
por: Whittaker, Cristen, et al.
Publicado: (2018)

447. Disease Progression in Patients with Acute Bacterial Skin and Skin Structure Infections: A Comparative Analysis Between Oritavancin and Vancomycin
por: Whittaker, Cristen A, et al.
Publicado: (2019)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway
por: Whittaker, Cristen, et al.
Publicado: (2020)

Impact of Outpatient vs Inpatient ABSSSI Treatment on Outcomes: A Retrospective Observational Analysis of Medical Charts Across US Emergency Departments
por: Bookstaver, P Brandon, et al.
Publicado: (2018)

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
por: Kmeid, Joumana, et al.
Publicado: (2015)

Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis
por: Johnson, Jennifer A., et al.
Publicado: (2015)

Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
por: Anastasio, Patrick J., et al.
Publicado: (2017)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

2289. Bacterial Causes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Intravenous Drug Use (IVDU): Phase 3 REVIVE Studies
por: Huang, David B, et al.
Publicado: (2019)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Patient Preferences in the Emergency Department (ED) Before Treatment for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2017)

Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections
por: Mitra, Subhashis, et al.
Publicado: (2015)

To Add or Not to Add: Would the Addition of Dalbavancin to Formulary Decrease Admissions for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)?
por: Freshwater, Dustin, et al.
Publicado: (2017)

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Rybak, Michael J, et al.
Publicado: (2017)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
por: Helton, Brittany, et al.
Publicado: (2020)

2377. Outcomes in Patients With History of Cardiac or Vascular Disease (CV) During Treatment of Acute Bacterial Skin And Skin Structure Infection (ABSSSI) With Delafloxacin (DLX) vs. Vancomycin/Aztreonam (VAN/AZ)
por: Oguchi, Godson, et al.
Publicado: (2018)

Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials
por: De Anda, Carisa, et al.
Publicado: (2017)

2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy
por: Pullman, John, et al.
Publicado: (2018)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

471. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI)
por: Bradley, John S, et al.
Publicado: (2019)

Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals
por: Bai, Francesca, et al.
Publicado: (2023)

Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective
por: Zinzi, Daniela, et al.
Publicado: (2022)

456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial
por: McCarthy, Matthew W, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mkkq9a8dhcr97p65fdfhsr23cl